NAMS
NAMS
NL00150012L7
NewAmsterdam Pharma Company N.V
Loading chart...

Financials

Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
Breakdown 2025 2024 Change %
Total Revenue 22.503.000 45.563.000
50.6%
Cost of Revenue -- --
--
Gross Profit -- --
--
248.186.000 221.852.000
11.9%
Operating Income -225.683.000 -176.289.000
28.0%
Pretax Income -203.819.000 -241.599.000
15.6%
Net Income Common Stockholders -203.819.000 -241.598.000
15.6%
-- --
--
-- --
--
ende